Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Merck Signs Cancer Pact With Avalon
March 12, 2007
| A version of this story appeared in
Volume 85, Issue 11
Merck has joined forces with Avalon Pharmaceuticals to discover and develop inhibitors for an undisclosed cancer target. Avalon will deploy its drug-screening platform to choose a set of compounds from Merck's library and identify hits against the cancer target. Avalon will then pick compound families to optimize into preclinical candidates. Those compounds will be handed off to Merck for clinical development and commercialization. The deal could be worth up to $200 million in milestones for Avalon.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter